HC Wainwright & Co. analyst Yi Chen downgrades Interpace Biosciences (OTC:IDXG) from Buy to Neutral.
HC Wainwright & Co. Downgrades Interpace Biosciences to Neutral
HC Wainwright & Co. analyst Yi Chen downgrades Interpace Biosciences (OTC:IDXG) from Buy to Neutral.
Related Posts
Goldman Sachs Initiates Coverage On Fate Therapeutics with Sell Rating, Announces Price Target of $10
Goldman Sachs analyst Andrea Tan initiates coverage on Fate Therapeutics (NASDAQ:FATE) with a Sell rating and announces Price Target of $10.
Pelosi Effect? Why Key Apple Supplier TSMC’s Shares Are Slipping Today
Shares of chipmaker Taiwan Semiconductor Mfg. Co. Ltd. (NYSE: TSM) fell as much as 2.98% in Asia trading on Tuesday after China expressed anger at reports of U.S. House Speaker Nancy Pelosi making a possible trip to Taiwan later in the day.